Genentech’s new partner Affimed NV has halted two blood cancer programmes with its tetravalent bispecific T cell engager AFM11 after a death and two cases of severe neurotoxicity occured in Phase I trails.
https://european-biotechnology.com/wp-content/uploads/2024/04/AFFIMED.jpg6561373Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-10-10 08:11:232018-10-10 08:11:23Affimed halts trial after patient death and SAEs
Aglaris Ltd. yesterday announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_online_stevendocksey.jpg400400h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-10-09 16:50:272018-10-09 16:50:27Aglaris Appoints New CEO
The Innovative Medicines Initiative 2 (IMI2) has launched a new Antimicrobial Resistance Accelerator Programme following on the heels of its outgoing NewDrugs4BadBugs programme.
Oxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and GlaxoSmithKline plc participated in this financing.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cell_Metabolism.jpg19902250Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-10-09 05:29:182018-10-09 05:29:18Sitryx Therapeutics bags $30m in Series A Financing
Exscientia, a company in Artificial Intelligence (AI)-driven drug discovery, has announced the appointment of Mr Georgy Egorov as Chief Financial Officer (CFO).
British gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow to balance its costs, which rose from US$13m to US$138m this year. Financial markets are expected to react positively.
Diagnostics company sphingotec GmbH successfully closed a €20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners.
Evotec and Sanofi have launched a Public Private Partnership (PPP) aimed at partnering with academic groups in early stage drug discovery across multiple therapeutic areas.
Researchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds.
Medigene is developing the next generation of effective TCR cell therapies aimed at establishing better control over cancer at reasonable production cost.
Affimed halts trial after patient death and SAEs
Latest NewsGenentech’s new partner Affimed NV has halted two blood cancer programmes with its tetravalent bispecific T cell engager AFM11 after a death and two cases of severe neurotoxicity occured in Phase I trails.
Aglaris Appoints New CEO
AppointmentsAglaris Ltd. yesterday announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.
IMI fosters antibiotics research amidst Big Pharma pullbacks
BackgroundThe Innovative Medicines Initiative 2 (IMI2) has launched a new Antimicrobial Resistance Accelerator Programme following on the heels of its outgoing NewDrugs4BadBugs programme.
Sitryx Therapeutics bags $30m in Series A Financing
Latest NewsOxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and GlaxoSmithKline plc participated in this financing.
Exscientia Appoints Georgy Egorov as CFO
AppointmentsExscientia, a company in Artificial Intelligence (AI)-driven drug discovery, has announced the appointment of Mr Georgy Egorov as Chief Financial Officer (CFO).
Orchard plans to raise US$172m in ADS
Latest NewsBritish gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow to balance its costs, which rose from US$13m to US$138m this year. Financial markets are expected to react positively.
Sphingotec raises €20m in growth equity financing
Latest NewsDiagnostics company sphingotec GmbH successfully closed a €20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners.
Sanofi and Evotec launch drug discovery PPP
Latest NewsRoche providing improved anti-Her2 bispecific antibody
Latest NewsResearchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds.
A new treatment paradigm
Sponsored PublicationsMedigene is developing the next generation of effective TCR cell therapies aimed at establishing better control over cancer at reasonable production cost.